CC...Conrad Clyburn (Clymer Grp)'s Groups (14)

Pfeiffer Touts Interstate Insurance And National Health Plans Like They're ... - Firedoglake (blog)

Pfeiffer Touts Interstate Insurance And National Health Plans Like They're ... Firedoglake (blog) That was how we got a stimulus package with 40% tax cuts, which was too small for the job. And that's how we're getting a health care bill which includes ...

The Faux Deficit Debate - True/Slant

The Faux Deficit Debate True/Slant That's probably where this debate is going: the press is going to agree to call the stimulus and health care “spending,” while pundits who discuss the ... Where Does Karl Rove Find the Nerve to Criticize Anyone About Deficits? Sullivan Challenges Rove

New York: Wall Street profits soar, education and health care face the ax - Axis of Logic

LongIslandPress.com

New York: Wall Street profits soar, education and health care face the ax Axis of Logic In view of the fact that the stimulus ends next year, this proposal would result in an even greater shortfall in the future. The reluctance of the Senate ... Health groups: Budget cuts risk layoffs Skelos, Paterson Fight Over Budget

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero, GmbH: Series A $15.9M

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

3Q09 OnBioVC | Trend Analysis Now Available

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

September 2009 OnBioVC | Trend Analysis Now Available

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]